Market News / Story
Biohaven (BHVN) Licenses IgG Degraders to Ono; BHV-1300 in Phase 3
·
Biohaven entered a licensing agreement with Ono Pharma covering extracellular IgG degraders in Japan and select Asian regions. Lead candidate BHV-1300 is in Phase 3 for Graves' disease. Material Details #DetailAI Analyst View1Licensing deal with Ono PharmaSignals regional monetization and partner validation; could add milestones/royalties if terms are meaningful.2Covers Japan and select AsiaExpands potential market access without Biohaven building its own…